KALA BIO plunges 92% after phase 2 failure of eye condition drug
Source: SeekingAlpha
2025-09-29 08:56:58 ET
More on KALA BIO
- Seeking Alpha’s Quant Rating on KALA BIO
- Historical earnings data for KALA BIO
- Financial information for KALA BIO
Read the full article on Seeking Alpha
For further details see:
KALA BIO plunges 92% after phase 2 failure of eye condition drug
Bio-Rad Laboratories Inc. Class A
NASDAQ: BIO
BIO Trading
11.13% G/L:
$276.50 Last:
456,908 Volume:
$274.72 Open:
BIO Latest News
BIO Stock Data
$8,088,674,023
21,121,296
0.01%
179
N/A
Biotechnology & Life Sciences
Healthcare
US
Hercules
